21/03/08
A new logo for Stallergenes

Category: Group activities

In order to pursue its development and to reach its future objectives, Stallergenes is adopting a new logo.

12/03/08
2007 Results

Category: Group activities, Finance

Further profit growth; Sales up 16%;

Profit before R&D up 19%;

Net profit (group share) up 12%;

Acceleration of R&D expenditure

15/01/08
Quarterly information

2007: A further year of strong growth: up 16%

13/12/07
Partnership for producing mites recombinant allergens

Category: R&D

Partnership agreement between STALLERGENES and PROTEIN’EXPERT

28/11/07
Oralair® Grasses: Positive results of VO52.06 paediatric study

Category: Group activities, Finance

The results of a study on children confirmed the efficacy of the ORALAIR® Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.

28/08/07
2007 half-year results

Strong business growth +17%

Earnings per share up 30%

14/05/07
Stallergenes and CMC BIOPHARMACEUTICALS sign manufacturing agreement

Signature of an agreement for development and supply of recombinant Bet v 1 (rBet v 1) purified bulk.

15/03/07
Increase in operating profit and additional R&D efforts

Category: Finance

2006: Another year of growth

13/02/07
STALLERGENES enters the Netherlands through a joint-venture agreement

15/01/07
Strong 13% 2006 full-year growth,2006 4th quarter sales up 13%

09/01/07
STALLERGENES and Paladin Labs sign a partnership for OralairTM in Canada